Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor

Vaccine

Volumn 30, Issue 45, 2012, Pages 6359-6367

  Do, Yoonkyung ^a,b,f   Didierlaurent, Arnaud M ^a   Ryu, Seongho ^c,g   Koh, Hyein ^a   Park, Chae Gyu ^a   Park, Steven ^d   Perlin, David S ^d   Powell, Bradford S ^e   Steinman, Ralph M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b Ulsan National Institute of Science and Technology   (South Korea)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^e UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^f GSK   (Belgium)

^g Cernomics Solutions   (United States)

Author keywords

CD205 DEC 205; Cellular immunity; Dendritic cells; LcrV; Mucosal; Y. pestis

Indexed keywords

ALPHA DEC 205 RECEPTOR ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; PLAGUE VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN LCRV; RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS PROTEIN V;

ADJUVANT THERAPY; AIRWAY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL VIRULENCE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; IMMUNIZATION; LUNG; MOUSE; MUCOSA; NONHUMAN; PLAGUE; PRIORITY JOURNAL; SURVIVAL; YERSINIA PESTIS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LECTINS, C-TYPE; LUNG; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; PLAGUE; PLAGUE VACCINE; POLY I-C; PORE FORMING CYTOTOXIC PROTEINS; RECEPTORS, CELL SURFACE; YERSINIA PESTIS;

EID: 84866547636     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.051     Document Type: Article

References (29)

1. Lathem W.W., Crosby S.D., Miller V.L., Goldman W.E. Progression of primary pneumonic plague: a mouse model of infection, pathology, and bacterial transcriptional activity. Proc Natl Acad Sci U S A 2005, 102(December (49)):17786-17791.
2. Bubeck S.S., Cantwell A.M., Dube P.H. Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice. Infect Immun 2007, 75(February (2)):697-705.
3. Reed D.S., Martinez M.J. Respiratory immunity is an important component of protection elicited by subunit vaccination against pneumonic plague. Vaccine 2006, 24(March (13)):2283-2289.
4. Eyles J.E., Williamson E.D., Spiers I.D., Alpar H.O. Protection studies following bronchopulmonary and intramuscular immunisation with yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy. Vaccine 2000, 18(August (28)):3266-3271.
5. Baca-Estrada M.E., Foldvari M.M., Snider M.M., Harding K.K., Kournikakis B.B., Babiuk L.A., et al. Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses. Vaccine 2000, 18(April (21)):2203-2211.
6. Eyles J.E., Sharp G.J., Williamson E.D., Spiers I.D., Alpar H.O. Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine 1998, 16(April (7)):698-707.
7. Jones T., Adamovicz J.J., Cyr S.L., Bolt C.R., Bellerose N., Pitt L.M., et al. Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. Vaccine 2006, 24(March (10)):1625-1632.
8. Honko A.N., Sriranganathan N., Lees C.J., Mizel S.B. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 2006, 74(February (2)):1113-1120.
9. Hill J., Eyles J.E., Elvin S.J., Healey G.D., Lukaszewski R.A., Titball R.W. Administration of antibody to the lung protects mice against pneumonic plague. Infect Immun 2006, 74(May (5)):3068-3070.
10. Nakajima R., Brubaker R.R. Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. Infect Immun 1993, 61(January (1)):23-31.
11. Elvin S.J., Williamson E.D. Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague. Microb Pathog 2004, 37(October (4)):177-184.
12. Parent M.A., Berggren K.N., Kummer L.W., Wilhelm L.B., Szaba F.M., Mullarky I.K., et al. Cell-mediated protection against pulmonary Yersinia pestis infection. Infect Immun 2005, 73(November (11)):7304-7310.
13. Parent M.A., Wilhelm L.B., Kummer L.W., Szaba F.M., Mullarky I.K., Smiley S.T. Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection. Infect Immun 2006, 74(June (6)):3381-3386.
14. Lin J.S., Park S., Adamovicz J.J., Hill J., Bliska J.B., Cote C.K., et al. TNFalpha and IFNgamma contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague. Vaccine 2010, 29(December (2)):357-362.
15. Lin J.S., Kummer L.W., Szaba F.M., Smiley S.T. IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection. J Immunol 2011, 186(February (3)):1675-1684.
16. Do Y., Park C.G., Kang Y.S., Park S.H., Lynch R.M., Lee H., et al. Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells. Eur J Immunol 2008, 38(January (1)):20-29.
17. Do Y., Koh H., Park C.G., Dudziak D., Seo P., Mehandru S., et al. Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague. Eur J Immunol 2010, 40(October (10)):2791-2796.
18. Powell B.S., Andrews G.P., Enama J.T., Jendrek S., Bolt C., Worsham P., et al. Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol Prog 2005, 21(September-October (5)):1490-1510.
19. Didierlaurent A., Goulding J., Patel S., Snelgrove R., Low L., Bebien M., et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 2008, 205(February (2)):323-329.
20. Heath D.G., Anderson G.W., Mauro J.M., Welkos S.L., Andrews G.P., Adamovicz J., et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 1998, 16(July (11-12)):1131-1137.
21. Perry R.D., Fetherston J.D. Yersinia pestis - etiologic agent of plague. Clin Microbiol Rev 1997, 10(January (1)):35-66.
22. Inglesby T.V., Dennis D.T., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2000, 283(May (17)):2281-2290.
23. Pitt ML. Animal models and correlates of protection for Plague Vaccines Workshop, Gaithersburg, MD. [13-14 October 2004]. http://wwwfdagov/cber/minutes/workshop-minhtm.
24. Wang B., Zaidi N., He L.Z., Zhang L., Kuroiwa J.M., Keler T., et al. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res 2012, 14(March (2)):R39.
25. Robinson R.A., DeVita V.T., Levy H.B., Baron S., Hubbard S.P., Levine A.S. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst 1976, 57(September (3)):599-602.
26. Stahl-Hennig C., Eisenblatter M., Jasny E., Rzehak T., Tenner-Racz K., Trumpfheller C., et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 2009, 5(April (4)):e1000373.
27. Lefrancois L., Puddington L. Intestinal and pulmonary mucosal T cells: local heroes fight to maintain the status quo. Annu Rev Immunol 2006, 24:681-704.
28. Harris N.L., Watt V., Ronchese F., Le Gros G. Differential T cell function and fate in lymph node and nonlymphoid tissues. J Exp Med 2002, 195(February (3)):317-326.
29. Williamson E.D., Vesey P.M., Gillhespy K.J., Eley S.M., Green M., Titball R.W. An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin Exp Immunol 1999, 116(April (1)):107-114.